The bone scan as a tumour marker in prostatic carcinoma

G. D. Chisholm, Anthony R Stone, L. L. Beynon, M. V. Merrick

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The technetium methylene diphosphate bone scan was evaluated in 100 consecutive new patients presenting with carcinoma of the prostate. 48% of the patients had a positive bone scan at the initial diagnosis. The scan was more more helpful than the skeletal X-ray in the diagnosis of bone metastases: 23% of the X-ray-negative patients were scan-positive. Serial bone scans were more sensitive than either X-rays or serum acid phosphatase in following the progress of the disease. It is concluded that the bone scan in patients with prostatic carcinoma can be used as a reliable tumour marker, especially for monitoring the course of metastases.

Original languageEnglish (US)
Pages (from-to)257-260
Number of pages4
JournalEuropean Urology
Volume8
Issue number5
StatePublished - 1982
Externally publishedYes

Fingerprint

Tumor Biomarkers
Carcinoma
Bone and Bones
X-Rays
Neoplasm Metastasis
Diphosphates
Technetium
Acid Phosphatase
Prostate
Serum

ASJC Scopus subject areas

  • Urology

Cite this

Chisholm, G. D., Stone, A. R., Beynon, L. L., & Merrick, M. V. (1982). The bone scan as a tumour marker in prostatic carcinoma. European Urology, 8(5), 257-260.

The bone scan as a tumour marker in prostatic carcinoma. / Chisholm, G. D.; Stone, Anthony R; Beynon, L. L.; Merrick, M. V.

In: European Urology, Vol. 8, No. 5, 1982, p. 257-260.

Research output: Contribution to journalArticle

Chisholm, GD, Stone, AR, Beynon, LL & Merrick, MV 1982, 'The bone scan as a tumour marker in prostatic carcinoma', European Urology, vol. 8, no. 5, pp. 257-260.
Chisholm GD, Stone AR, Beynon LL, Merrick MV. The bone scan as a tumour marker in prostatic carcinoma. European Urology. 1982;8(5):257-260.
Chisholm, G. D. ; Stone, Anthony R ; Beynon, L. L. ; Merrick, M. V. / The bone scan as a tumour marker in prostatic carcinoma. In: European Urology. 1982 ; Vol. 8, No. 5. pp. 257-260.
@article{f4f8037d400b4c8fbd7aa83827ab7c0b,
title = "The bone scan as a tumour marker in prostatic carcinoma",
abstract = "The technetium methylene diphosphate bone scan was evaluated in 100 consecutive new patients presenting with carcinoma of the prostate. 48{\%} of the patients had a positive bone scan at the initial diagnosis. The scan was more more helpful than the skeletal X-ray in the diagnosis of bone metastases: 23{\%} of the X-ray-negative patients were scan-positive. Serial bone scans were more sensitive than either X-rays or serum acid phosphatase in following the progress of the disease. It is concluded that the bone scan in patients with prostatic carcinoma can be used as a reliable tumour marker, especially for monitoring the course of metastases.",
author = "Chisholm, {G. D.} and Stone, {Anthony R} and Beynon, {L. L.} and Merrick, {M. V.}",
year = "1982",
language = "English (US)",
volume = "8",
pages = "257--260",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The bone scan as a tumour marker in prostatic carcinoma

AU - Chisholm, G. D.

AU - Stone, Anthony R

AU - Beynon, L. L.

AU - Merrick, M. V.

PY - 1982

Y1 - 1982

N2 - The technetium methylene diphosphate bone scan was evaluated in 100 consecutive new patients presenting with carcinoma of the prostate. 48% of the patients had a positive bone scan at the initial diagnosis. The scan was more more helpful than the skeletal X-ray in the diagnosis of bone metastases: 23% of the X-ray-negative patients were scan-positive. Serial bone scans were more sensitive than either X-rays or serum acid phosphatase in following the progress of the disease. It is concluded that the bone scan in patients with prostatic carcinoma can be used as a reliable tumour marker, especially for monitoring the course of metastases.

AB - The technetium methylene diphosphate bone scan was evaluated in 100 consecutive new patients presenting with carcinoma of the prostate. 48% of the patients had a positive bone scan at the initial diagnosis. The scan was more more helpful than the skeletal X-ray in the diagnosis of bone metastases: 23% of the X-ray-negative patients were scan-positive. Serial bone scans were more sensitive than either X-rays or serum acid phosphatase in following the progress of the disease. It is concluded that the bone scan in patients with prostatic carcinoma can be used as a reliable tumour marker, especially for monitoring the course of metastases.

UR - http://www.scopus.com/inward/record.url?scp=0019918999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019918999&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 257

EP - 260

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -